Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
10:17am, Tuesday, 02'nd Apr 2024
AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
10:06am, Tuesday, 02'nd Apr 2024
FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.
Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:06pm, Monday, 01'st Apr 2024
Astrazeneca (AZN) concluded the recent trading session at $67.25, signifying a -0.74% move from its prior day's close.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 29'th Mar 2024
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
09:08am, Thursday, 28'th Mar 2024
Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.
AstraZeneca CEO Soriot on Pharmaceuticals in China
09:27pm, Tuesday, 26'th Mar 2024
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sideline
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
06:56pm, Tuesday, 26'th Mar 2024
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
11:01am, Tuesday, 26'th Mar 2024
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
03:41pm, Wednesday, 20'th Mar 2024
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
12:51pm, Wednesday, 20'th Mar 2024
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
01:00am, Wednesday, 20'th Mar 2024
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:56pm, Tuesday, 19'th Mar 2024
Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
02:51pm, Tuesday, 19'th Mar 2024
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Biotech Stock Soars on AstraZeneca Buyout
10:50am, Tuesday, 19'th Mar 2024
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.
